From 9 to 11 October, 2012, Grindeks will participate in the international exhibition “CPhI Worldwide 2012” in Madrid, Spain. During the exhibition Grindeks will meet with its existing and potential business partners, as well as introduce visitors to its world class products and services. Grindeks exhibition stand will be placed in the Hall 9 with number 9B58.
Grindeks will promote cooperation in the following business fields:
Complicated, multi-stage synthesis of APIs;
FDF development and manufacturing of tablets, capsules, injections and topical forms;
Customized contract manufacturing of FDF.
Another significant type of Grindeks cooperation with other pharmaceutical companies is raw material purchases for manufacturing purposes. Therefore, during the exhibition “CPhI Worldwide 2012” the company has an opportunity of meeting the leading respective cooperation offerers. Grindeks goal is finding the most economically advantageous tender for the raw material purchases.
Chairman of the Board of JSC Grindeks Juris Bundulis admits: “This is a yearly, important pharmaceutical event; therefore, taking into account the successful experience in previous years, we will participate at the exhibition for the fifth year in a row. At the exhibition we will meet our existing clients, as well as seek for new, perspective cooperation opportunities. Undoubtedly, participation at the exhibition is as an acknowledgement for our competitiveness with other pharmaceutical companies. Grindeks is a development-oriented company that has many advantages to compete successfully in the global pharmaceutical market. Our reputation, solutions and products are appreciated by our cooperation partners, health-care specialists and patients.”
“CPhI Worldwide” is the world’s most important pharmaceutical event, which, in 2012, is held for the 23rd time and gathers pharmaceutical product manufacturers and related industry representatives from all over the world.
The participation of Grindeks in “CPhI Worldwide 2012” is co-financed by the European Regional Development Fund.
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries.
Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently Grindeks produces 22 active pharmaceutical ingredients.
Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010 The Ministry of Economics of Republic of Latvia and Investment and Development Agency of Latvia awarded Grindeks as the most export potential company of Latvia.
During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years.
JSC Grindeks shares are listed in the Official List of „Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans –33.29%, Anna Lipmane – 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda Banken” (nominal holder) – 10.53%, “Swedbank” AS Clients Account (nominal holder) – 8.79%.
More information about the company – www.grindeks.lv/en/
Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505